{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"77","upperLimit":"100","value":"90"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"Overall survival (OS) will be measured from treatment initiation until death from any cause for up to 1 year post-treatment discontinuation. Overall survival is defined as the duration of time from start of treatment to time of death. All patients who have had at least one dose of study treatment will be evaluable for OS. OS will be reported as percentage of participants alive at 2 years post treatment discontinuation, with censoring of patients who are lost to follow-up.","dispersionType":"90% Confidence Interval","groups":[{"description":"Induction:\n\n* Brentuximab vedotin 1.2 mg/kg IV infusion over 30 minutes, weekly x 3 (1 cycle = 4 weeks\n* Rituximab 375 mg/m2 IV infusion per standard protocol, once weekly for 4 weeks (1 cycle = 4 weeks)\n\nConsolidation (optional): Identical to Induction.\n\nMaintenance:\n\n* Brentuximab vedotin 1.8 mg/kg IV infusion over 30 minutes once every 3 weeks (1 cycle = 3 weeks), for a total of one year from the first induction dose or until progression of disease.\n* Rituximab 375 mg/m2 IV infusion per standard protocol, once every 6 weeks for a total of one year from the first induction dose or until progression of disease.","id":"OG000","title":"Brentuximb Vedotin Dose Level 1 (1.2 mg/kg)"}],"paramType":"NUMBER","populationDescription":"One patient was censored from overall survival because they were lost to follow-up.","reportingStatus":"POSTED","timeFrame":"From start of treatment to 2 years post treatment discontinuation","title":"Percentage of Participants Alive at 2 Years (Overall Survival)","type":"SECONDARY","unitOfMeasure":"percent of participants"}